Arbutus Biopharma Corporation - Product Pipeline Review - 2016

1 of 3
Arbutus Biopharma Corporation - Product Pipeline Review - 2016

Summary

‘Arbutus Biopharma Corporation - Product Pipeline Review - 2016’, provides an overview of the Arbutus Biopharma Corporation’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Arbutus Biopharma Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Arbutus Biopharma Corporation
- The report provides overview of Arbutus Biopharma Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Arbutus Biopharma Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Arbutus Biopharma Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Arbutus Biopharma Corporation’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Arbutus Biopharma Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Arbutus Biopharma Corporation’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 3
List of Tables

List of Figures

Arbutus Biopharma Corporation Snapshot

Arbutus Biopharma Corporation Overview

Key Information

Key Facts

Arbutus Biopharma Corporation - Research and Development Overview

Key Therapeutic Areas

Arbutus Biopharma Corporation - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Arbutus Biopharma Corporation - Pipeline Products Glance

Arbutus Biopharma Corporation - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Arbutus Biopharma Corporation - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Arbutus Biopharma Corporation - Drug Profiles

ARB-1467

Product Description

Mechanism of Action

R&D Progress

AB-423

Product Description

Mechanism of Action

R&D Progress

ARB-1740

Product Description

Mechanism of Action

R&D Progress

ARB-199

Product Description

Mechanism of Action

R&D Progress

ARB-596

Product Description

Mechanism of Action

R&D Progress

CCC-0346

Product Description

Mechanism of Action

R&D Progress

CCC-0975

Product Description

Mechanism of Action

R&D Progress

CYT-003QbG10

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit HBsAg for Hepatitis B

Product Description

Mechanism of Action

R&D Progress

DVR-23

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Hepatitis B Infection

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Agonize Sting Receptor for Hepatitis B

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit Ribonuclease H for Hepatitis B

Product Description

Mechanism of Action

R&D Progress

Arbutus Biopharma Corporation - Pipeline Analysis

Arbutus Biopharma Corporation - Pipeline Products by Target

Arbutus Biopharma Corporation - Pipeline Products by Route of Administration

Arbutus Biopharma Corporation - Pipeline Products by Molecule Type

Arbutus Biopharma Corporation - Pipeline Products by Mechanism of Action

Arbutus Biopharma Corporation - Recent Pipeline Updates

Arbutus Biopharma Corporation - Dormant Projects

Arbutus Biopharma Corporation - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

INX-3280

NVP-018

RNAi Oligonucleotide to Inhibit CSN5 for Hepatocellular Carcinoma

RNAi Oligonucleotide to Inhibit WEE1 for Hepatocellular Carcinoma

Small Molecules for Dengue

TKM-100802

TKM-130803

TKM-ALDH2

TKM-GSD

TKM-HTG

TKM-Marburg

TKM-PLK1

TKMApoC-3

Arbutus Biopharma Corporation - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 49List of Tables

Arbutus Biopharma Corporation, Key Information

Arbutus Biopharma Corporation, Key Facts

Arbutus Biopharma Corporation - Pipeline by Indication, 2016

Arbutus Biopharma Corporation - Pipeline by Stage of Development, 2016

Arbutus Biopharma Corporation - Monotherapy Products in Pipeline, 2016

Arbutus Biopharma Corporation - Partnered Products in Pipeline, 2016

Arbutus Biopharma Corporation - Partnered Products/ Combination Treatment Modalities, 2016

Arbutus Biopharma Corporation - Out-Licensed Products in Pipeline, 2016

Arbutus Biopharma Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016

Arbutus Biopharma Corporation - Phase II, 2016

Arbutus Biopharma Corporation - Preclinical, 2016

Arbutus Biopharma Corporation - Discovery, 2016

Arbutus Biopharma Corporation - Pipeline by Target, 2016

Arbutus Biopharma Corporation - Pipeline by Route of Administration, 2016

Arbutus Biopharma Corporation - Pipeline by Molecule Type, 2016

Arbutus Biopharma Corporation - Pipeline Products by Mechanism of Action, 2016

Arbutus Biopharma Corporation - Recent Pipeline Updates, 2016

Arbutus Biopharma Corporation - Dormant Developmental Projects,2016

Arbutus Biopharma Corporation - Discontinued Pipeline Products, 2016

Arbutus Biopharma Corporation, Subsidiaries 47List of Figures

Arbutus Biopharma Corporation - Pipeline by Stage of Development, 2016

Arbutus Biopharma Corporation - Monotherapy Products in Pipeline, 2016

Arbutus Biopharma Corporation - Partnered Products in Pipeline, 2016

Arbutus Biopharma Corporation - Out-Licensed Products in Pipeline, 2016

Arbutus Biopharma Corporation - Pipeline by Target, 2016

Arbutus Biopharma Corporation - Pipeline by Route of Administration, 2016

Arbutus Biopharma Corporation - Pipeline by Molecule Type, 2016

Arbutus Biopharma Corporation - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll